Published in Exp Hematol Oncol on October 08, 2013
IL-2 "SELECT" Tissue Collection Protocol in Patients With Advanced Melanoma | NCT01288963
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature (2000) 64.32
The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med (2002) 24.07
Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood (2003) 13.92
Stromal gene signatures in large-B-cell lymphomas. N Engl J Med (2008) 11.34
Assembly of fibronectin extracellular matrix. Annu Rev Cell Dev Biol (2010) 2.86
A new biologic prognostic model based on immunohistochemistry predicts survival in patients with diffuse large B-cell lymphoma. Blood (2012) 1.68
De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients. Blood (2002) 1.52
Fibronectin as target for tumor therapy. Int J Cancer (2006) 1.44
Modulation of matrix remodeling by SPARC in neoplastic progression. Semin Cell Dev Biol (2009) 1.44
Molecular and immunological dissection of diffuse large B cell lymphoma: CD5+, and CD5- with CD10+ groups may constitute clinically relevant subtypes. Leukemia (1999) 1.07
The tumour-targeting human L19-IL2 immunocytokine: preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma. Eur J Cancer (2010) 1.05
The stromal cell marker SPARC predicts for survival in patients with diffuse large B-cell lymphoma treated with rituximab. Am J Clin Pathol (2011) 1.00
Expression profiling analysis of the CD5+ diffuse large B-cell lymphoma subgroup: development of a CD5 signature. Cancer Sci (2006) 0.88
A new diagnostic algorithm for Burkitt and diffuse large B-cell lymphomas based on the expression of CSE1L and STAT3 and on MYC rearrangement predicts outcome. Ann Oncol (2012) 0.84
Fibronectin gene polymorphisms are associated with the development of B-cell lymphoma in type II mixed cryoglobulinemia. Ann Rheum Dis (2007) 0.80
Surviving 20 years after heart transplantation: a success story. Ann Thorac Surg (2013) 1.54
Cancer testis antigen expression in testicular germ cell tumorigenesis. Mod Pathol (2013) 1.45
Targeting the mTOR Complex by Everolimus in NRAS Mutant Neuroblastoma. PLoS One (2016) 1.41
Does body mass index impact the early outcome of surgical revascularization? A comparison between off-pump and on-pump coronary artery bypass grafting. Interact Cardiovasc Thorac Surg (2014) 1.40
Imaging non-specific wrist pain: interobserver agreement and diagnostic accuracy of SPECT/CT, MRI, CT, bone scan and plain radiographs. PLoS One (2013) 0.87
Image-based computational quantification and visualization of genetic alterations and tumour heterogeneity. Sci Rep (2016) 0.85
EGFR and KRAS Mutations in ALK-Positive Lung Adenocarcinomas: Biological and Clinical Effect. Clin Lung Cancer (2015) 0.78
Detection of CCNE1/URI (19q12) amplification by in situ hybridisation is common in high grade and type II endometrial cancer. Oncotarget (2017) 0.75
Lack of MRE11-RAD50-NBS1 (MRN) complex detection occurs frequently in low-grade epithelial ovarian cancer. BMC Cancer (2017) 0.75
Chromosomal aberrations of cancer-testis antigens in myeloma patients. Hematol Oncol (2014) 0.75
Effect of Peripheral Artery Sympathetic Denervation on Muscle Microperfusion and Macroperfusion in an Animal Peripheral Artery Disease Model Using Contrast-Enhanced Ultrasound and Doppler Flow Measurement. J Vasc Interv Radiol (2015) 0.75
The combined expression of VPREB3 and ID3 represents a new helpful tool for the routine diagnosis of mature aggressive B-cell lymphomas. Hematol Oncol (2013) 0.75